By Bonnie Milas, MD
The FDA approved naloxone at the end of March as an over-the-counter (OTC) medication, vastly increasing our ability to tackle the opioid epidemic, save lives and improve public health. As a physician and mother who, unfortunately, has firsthand experience with the impact of the epidemic, and one who provided personal testimony to the FDA advisory panel hearing in February, I am gratified by the FDA’s decision.
Changing the status of naloxone to OTC is critically